Back to News
Market Impact: 0.3
FDA Grants Breakthrough Therapy Designation To Idorsia's Daridorexant For Pediatric Insomnia
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA granted Breakthrough Therapy Designation to Idorsia Pharmaceuticals’ daridorexant for insomnia disorder in children and adolescents aged 10 to under 18. The designation is a regulatory milestone, not an approval.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- China Blocks SoftBank Acquisition of ABB Robot Unit, FT Says
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- After the midterms, a bigger clash over data centers could be coming
- Voters rebuff data centers in every ballot measure except one during the 2026 midterms
- After the midterms, Big Tech’s AI data center problem is only getting bigger